Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Pradaxa Bellwether Lawsuits Selected for First Trial Dates in MDL January 24, 2014 Austin Kirk Add Your Comments Four Pradaxa lawsuits have been selected for early trial dates in the federal multidistrict litigation (MDL), which are scheduled to begin in the second half of this year. There are currently about 2,000 product liability lawsuits pending in the federal court system against Boehringer Ingelheim, which all involve similar allegations that side effects of Pradaxa caused users of the anticoagulant to suffer severe and sometimes fatal bleeding problems. Since August 2012, the federal Pradaxa litigation has been consolidated as part of an MDL, which is centralized before U.S. District Judge David R. Herndon in the Southern District of Illinois to reduce duplicative discovery, avoid conflicting rulings from different judges and to serve the convenience of the parties, witnesses and the courts. Learn More About Pradaxa Internal Bleeding Lawsuit Side effects of Pradaxa may increase risk of severe bleeding and death. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Pradaxa Internal Bleeding Lawsuit Side effects of Pradaxa may increase risk of severe bleeding and death. Learn More SEE IF YOU QUALIFY FOR COMPENSATION As part of the coordinated management of the cases, Judge Herndon has scheduled a series of early trial dates in the Pradaxa MDL, known as bellwether cases. These trials are set to begin between August 2014 and February 2015, with the outcomes designed to help the parties gauge how juries are likely respond to certain evidence and testimony that may be repeated throughout a large number of cases. In a Case Management Order (PDF) issued January 23, Judge Herndon identified four specific cases that will go forward for these Pradaxa bellwether trials. The first two trials will involve Pradaxa wrongful death lawsuits, where plaintiffs suffered fatal injuries as a result of uncontrollable bleeding. The first trial is set to begin on August 11, 2014, involving a complaint (PDF) brought by Suzanne Mackiewicz on behalf of her father, Malachy Higgins, with a trial set to begin on November 3, 2014, involving a complaint (PDF) filed by Nancy Kohn on behalf of her deceased husband, Ronald. Both cases involve men who suffered fatal bleeding complications while taking Pradaxa, alleging that Boehringer Ingelheim overstated the safety and effectiveness of the medication and that the drug maker should have warned doctors that there was no conventional way to stop Pradaxa bleeding. The third Pradaxa bellwether trial is scheduled to begin on January 5, 2015, involving a complaint (PDF) filed by Georgia Primus, who was hospitalized for six days after experiencing excessive upper gastrointestinal bleeding, which has left her needing lifelong medical treatment. The fourth bellwether trial will begin on February 6, 2015, involving a complaint (PDF) brought by Helen Jean and John Edward Hawkins, which also involves an upper gastrointestinal bleed that was allegedly caused by Pradaxa use. Pradaxa Bleeding Concerns Pradadxa (dabigatran) is a relatively new anticoagulant therapy that was approved by the FDA in October 2010. It was the first member of a new class of medications that are promoted as superior alternatives to warfarin, also known by the brand name Coumadin, for stroke prevention. However, shortly after its introduction, Pradaxa began to rack up a record number of adverse event reports after patients experienced uncontrolled bleeding events. Warfarin, sold under the brand name Coumadin, has been the go-to anticoagulant for decades. While Pradaxa does require less monitoring, concerns have emerged about the lack of an effective reversal agent to stop the blood thinning effects of the medication. Unlike warfarin, which can be quickly reversed with a dose of vitamin K and plasma, there is no available reversal agent for Pradaxa. While some studies have shown that the chances of bleeding may be about the same with the two drugs, evidence continues to emerge highlighting how Pradaxa bleeding problems may pose a more serious risk, since hemorrhages are typically harder to stop. During the first full year the drug was on the market in the United States, the Institute for Safe Medication Practices (ISMP) found that adverse event reports involving Pradaxa problems surpassed all other medications regularly monitored by the group. FDA received at least 3,781 reports involving serious injuries associated with the use of Pradaxa during 2011, including 2,367 reports of hemorrhage and 542 patient deaths. All of the claims pending throughout the federal court system involve similar allegations and the outcomes of the early bellwether trials may influence Pradaxa settlement negotiations in a number of other cases. Pradaxa Litigation Discovery Issues When the Pradaxa litigation was centralized before Judge Herndon, an aggressive pretrial schedule was established in an attempt to move the cases toward an “expeditious resolution” for the factual allegations, which was designed to benefit both plaintiffs and the drug maker. As a result of their bad faith conduct during the discovery phase of the litigation, Judge Herndon has already ordered Boehringer Ingelheim to pay nearly $1 million in sanctions for failure to preserve evidence critical to the cases and for providing what were described as highly dubious excuses. Juries in the bellwether cases may be told about the company’s behavior and to weigh the failure to preserve evidence in their deliberations. In another Case Management Order (PDF) issued January 23, Judge Herndon denied a motion for protective order filed by Boehringer Ingelheim, which sought to prevent plaintiffs from calling Dr. Andreas Barner to testify during the cases. Barner is the Chairman of the Board of Managing Directors of Boehringer Ingelheim, and was the head of research and development. The company tried to shield him from testifying by saying it was overly expensive due to his key position in the company and that plaintiffs could get the information they needed elsewhere. However, Judge Herndon points out that the company itself touts Barner as being a “hands on” director with research background and having unique insight into its products. While he denied the company’s request to protect Barner from being called to testify, Judge Herndon did grant another request to prevent the testimony of Allan Hillgrove, another board member, agreeing that plaintiffs could get anything he would have said on the stand from someone else. Tags: Blood Thinner, Boehringer Ingelheim, Gastrointestinal Bleeding, Internal Bleeding, Pradaxa, Wrongful Death More Pradaxa Lawsuit Stories Jury Awards $540K in Pradaxa Trial Against Boehringer Ingelheim May 21, 2019 Paragard IUD Lawsuit Dismissed on Summary Judgment February 25, 2019 Boehringer Ingelheim Ordered to Pay $1.25M For Failure to Warn About Pradaxa Bleeding Risks October 25, 2018 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermEmailThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Lawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (Posted: today) A Depo-Provera lawsuit blames the active ingredient, DMPA, for an increased risk of the development of brain tumors. MORE ABOUT: DEPO-PROVERA LAWSUITOrtho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)Pfizer Requests Depo-Provera Lawsuit Coordination as Mass Tort in Pennsylvania State Court (06/10/2025) Zantac Cancer Lawsuits Continue To Be Filed More Than 5 Years After Recall (Posted: 2 days ago) A man diagnosed with multiple forms of cancer has filed a Zantac lawsuit, blaming Boehringer Ingelheim for failing to adequately warn about the recalled heartburn drug’s health risks. MORE ABOUT: ZANTAC CANCER LAWSUITSJury Hears Zantac Cancer Evidence in Illinois Trial Against Boehringer Ingelheim (02/05/2025)Zantac Bladder Cancer Lawsuit Trial Ends With Hung Jury in California (11/22/2024)GSK To Pay $2.2 Billion To Settle Zantac Cancer Lawsuits Brought by 80,000 Consumers (10/10/2024) Enfamil NEC Lawsuit Filed After Newborn Suffers ‘Nearly Total Bowel Necrosis’ (Posted: 3 days ago) Necrotizing enterocolitis caused by Enfamil resulted in a newborn suffering life-long bowel injuries, according to a lawsuit filed by his mother. MORE ABOUT: ENFAMIL AND SIMILAC BABY FORMULA LAWSUITReckitt Benckiser Faces Class Action Lawsuit Over Enfamil NEC Risks (06/12/2025)NEC Infant Formula Lawyers To Meet With MDL Judge Following Dismissal of First Bellwether Trial (05/29/2025)FDA To Investigate Whether Infant Formula Products Provide Enough Nutrition (05/16/2025)
Boehringer Ingelheim Ordered to Pay $1.25M For Failure to Warn About Pradaxa Bleeding Risks October 25, 2018
Lawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (Posted: today) A Depo-Provera lawsuit blames the active ingredient, DMPA, for an increased risk of the development of brain tumors. MORE ABOUT: DEPO-PROVERA LAWSUITOrtho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)Pfizer Requests Depo-Provera Lawsuit Coordination as Mass Tort in Pennsylvania State Court (06/10/2025)
Zantac Cancer Lawsuits Continue To Be Filed More Than 5 Years After Recall (Posted: 2 days ago) A man diagnosed with multiple forms of cancer has filed a Zantac lawsuit, blaming Boehringer Ingelheim for failing to adequately warn about the recalled heartburn drug’s health risks. MORE ABOUT: ZANTAC CANCER LAWSUITSJury Hears Zantac Cancer Evidence in Illinois Trial Against Boehringer Ingelheim (02/05/2025)Zantac Bladder Cancer Lawsuit Trial Ends With Hung Jury in California (11/22/2024)GSK To Pay $2.2 Billion To Settle Zantac Cancer Lawsuits Brought by 80,000 Consumers (10/10/2024)
Enfamil NEC Lawsuit Filed After Newborn Suffers ‘Nearly Total Bowel Necrosis’ (Posted: 3 days ago) Necrotizing enterocolitis caused by Enfamil resulted in a newborn suffering life-long bowel injuries, according to a lawsuit filed by his mother. MORE ABOUT: ENFAMIL AND SIMILAC BABY FORMULA LAWSUITReckitt Benckiser Faces Class Action Lawsuit Over Enfamil NEC Risks (06/12/2025)NEC Infant Formula Lawyers To Meet With MDL Judge Following Dismissal of First Bellwether Trial (05/29/2025)FDA To Investigate Whether Infant Formula Products Provide Enough Nutrition (05/16/2025)